New Compound that Stimulates Immune Cells to Eliminate Cancers
None
Inventor: CHE, Chiming
Priority Number: WO2004024146A1
IPC Current: A61K0031555 | A61K00317072 | A61P003500
Assignee Applicant: The University of Hong Kong
Title: METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | PROCEDES D'UTILISATION DE COMPLEXES D'OR (III) EN TANT QU'AGENTS ANTI-TUMORAUX ET ANTI-VIH
Usefulness: METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | PROCEDES D'UTILISATION DE COMPLEXES D'OR (III) EN TANT QU'AGENTS ANTI-TUMORAUX ET ANTI-VIH
Summary: (A) is useful to induce apoptosis of cancer cells and also to inhibit human immunodeficiency virus-1 reverse transcriptase (claimed).
Novelty: Use of gold (III) complex to induce apoptosis of cancer cells and to inhibit human immunodeficiency virus-1 reverse transcriptase
生物醫學
醫藥成分
9205131
General Information Cytokines, such as interferon-alpha and interleukin-2, have been used to treat cancer patients with limited success. Unfortunately, these cytokines also have profound side effects that limit their use. A UC San Diego researcher has developed a novel method to treat and prevent cancer using the cytokine IL-17D which stimulates immune cells to eliminate cancers. Such an approach does not cause side effects seen with other pro-inflammatory members of the IL-17 family. Detailed description of technoogy is available under secrecy agreement. Tech ID/UC Case 22177/2011-202-0 Related Cases 2011-202-0
Efficacy of this new method has been shown in mouse models; initially with overexpression of IL-17D in implanted tumor lines, but more recently using exogenously applied IL-17D as would occur in clinical use. Although a full publication on this material is still pending, two abstracts may be reviewed at:
IL-17D mediated cancer rejection
Timothy O'Sullivan, Robert Saddawi-Konefka, and Jack Bui
美國
